DOI : 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 57 · March 2024 DOI: 10.1055/s-014-59266


XVth Symposium of the Task Force Therapeutic Drug Monitoring of the AGNP
Freiburg, Germany, 20.–22.03.2024

Organizing committee: Christian Fleischhaker, Hans-Willi Clement, Stefan Unterecker, Tom Utech, Eugenia Potapova
Program committee:
Stefan Unterecker / Chairman
Xenia Hart, Georgios Schoretsanitis,
Niels Bergemann, Hans-Willi Clement, Karin Egberts
Gerhard Gründer, Ursula Havemann-Reinecke, Gudrun Hefner,
Christoph Hiemke, Maike Scherf-Clavel
Abstracts (HTML) Abstracts (PDF) List of Authors
  • 27
    von Broen, M.; Scherf-Clavel, M.; Deckert, J.; Unterecker, S.:

    Sertraline concentration in serum unaffected by hemodialysis: a case report

  • 28
    Hagenkötter, S. S.; Egberts, K.; Fekete, S.; Gerlach, M.; Hiemke, C.; Rauh, R.; Clement, H.W.; Biscaldi, M.; Fleischhaker, C.:

    Systematic review on blood concentrations of ADHD medications in children and adolescents

  • 29
    Kaiser, A.; Egberts, K.; Clement, H.W.; Schneider-Momm, K.; Taurines, R.; Fekete, S.; Romanos, M.; Fleischhaker, C.:

    Therapeutic drug monitoring in children and adolescents using quetiapine for the treatment of schizophrenia and other psychotic disorders – results of a pharmacovigilance study

  • 30
    Amann, F. J.; Kochtyrev, M.; Zernig, G.; Gründer, G.; Hart, X. M.:

    Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis

  • 31
    Kuzo, N.; Piras, M.; Lutz, U. C.; Haen, E.; Eap, C. B.; Hiemke, C.; Paulzen, M.; Schoretsanitis, G.:

    Therapeutic reference range for clozapine plasma levels when prescribed in patients with Parkinson's disease or dementia: a three-center cohort study and meta-analysis

  • 32
    Ortmann, C.; Fekete, S.; Taurines, R.; Gerlach, M.; Romanos, M.; Egberts, K.:

    Venlafaxine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring trial

  • 33
    Scherf-Clavel, M.; Frantz, A.; Eckert, A.; Weber, H.; Unterecker, S.; Deckert, J.; Reif, A.; Hahn, M.:

    Equal contribution of pharmacogenetic phenotype and phenoconversion to functional CYP2D6 metabolizer status

  • 34
    Zioris, G.; Warrings, B.; Heiduk, S.; Deckert, J.; Unterecker, S.; Scherf-Clavel, M.:

    Drug-drug interaction between hydroxybupropion and venlafaxine – a pharmacokinetic study on CYP2D6

  • 35
    Spangemacher, M.; Schmitz, C.; Färber, L. V.; Hart, X. M.; Gründer, G.:

    PET-derived modelling of D2-receptor occupancy of antipsychotic polypharmacy in patients with schizophrenia

  • 36
    Spangemacher, M.; Hart, X.M.; Saalfrank, E.; Gründer, G.; Reinwald, J.; Sartorius, A.:

    Elevation of alpha-1 acid glycoprotein during acute infection increases clozapine levels without signs of intoxication

  • 37
    Taurines, R.; Kunkel, G.; Fekete, S.; Gerlach, M.; Romanos, M.; Egberts, K.:

    Fluvoxamine serum concentrations in children and adolescents – preliminary results of a multicenter Therapeutic Drug Monitoring (TDM) trial

  • 38
    Yagcioglu, Ü.; Schneider-Momm, K.; Kempf, J.; Hagenkötter, S. S.; Rauh, R.; Clement, H.W.; Schulz, E.; Biscaldi, M.; Fleischhaker, C.:

    Serum Levels of Methylphenidate and Efficacy Measures in Children With Attention-Deficit/Hyperactivity Disorder After Crossover Intake of Ritalin​ LA and Medikinet​ retard in a Classroom Setting.

  • 39
    Scherf-Clavel, M.; Deckert, J.; Unterecker, S.:

    Medical and economic benefits of routinely requested therapeutic drug monitoring of antidepressants

  • 40
    Amann, F. J.; Endres, K.; Hiemke, C.; Zernig, G.; Gründer, G.; Hart, X. M.:

    Update on dose-related reference ranges for psychotropic drugs

  • 41
    Jung, A.; Fekete, S.; Taurines, R.; Egberts, K.:

    Haloperidole serum concentrations in daily child and adolescent psychiatric practice